TH 1901
Alternative Names: Peptide-Curcumin Conjugate TH1901; TH1901Latest Information Update: 26 Mar 2024
At a glance
- Originator Theratechnologies
- Class Antineoplastics; Drug conjugates; Peptide drug conjugates
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 22 Mar 2024 TH 1901 is available for licensing as of 22 Mar 2024. https://www.theratech.com/medicines-pipeline/pipeline-and-science/oncology/sortilin
- 22 Mar 2024 Suspended - Preclinical for Cancer in Canada (unspecified route)
- 20 May 2020 Pharmacodynamics data from a preclinical study in Cancer presented at the American Association for Cancer Research virtual annual meeting (AACR-2020)